Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers have developed core/shell nanogels that can target cancer cells using folic acid, a nutrient that cancer cells absorb more than healthy cells. The nanoparticles can be heated to kill cancer cells, but applying targeted heat sources like ultrasound can spare healthy cells.
Researchers have discovered a small, Smac-like molecule that can encourage the death of cancer cells without harming normal cells. The compound mimics the natural protein Smac, which normally regulates cell death in healthy cells.
Researchers stiffened a critical protein 'death domain' to target and destroy leukemia cells, showing promise for novel cancer treatments. The approach uses natural sequences to develop highly specific drugs, potentially unlocking new therapies.
The green tea gum helps eliminate free radicals that can damage DNA and lead to cancer. It also protects healthy cells by targeting cancer cells for destruction.
A study published in Cancer Cell found that zebularine slows cancer-cell growth by up to 68%, but only 21% in normal cells. The drug works by demethylating specific genes, offering a promising new approach to cancer treatment with fewer side effects.
A mouse model of Werner's syndrome reveals a link between aging and cancer development, suggesting that telomere shortening accelerates disease progression. The study suggests that genomic instability is a common denominator in both aging and cancer, with telomere length playing a key role.
Researchers use a novel chemical reaction in living mice to tag cells and attach tracer molecules to sugars on cell surfaces. This technique could help doctors pinpoint inflamed or cancerous cells for diagnosis. The method allows for the exploration of biosynthetic pathways and the examination of functional consequences.
A research team has identified a new pathway for the display of foreign proteins to the immune system, distinct from the conventional TAP-dependent pathway. This alternative pathway requires cysteine proteases and contributes to immunity against viruses and transplanted tissues.
Researchers discover Rho proteins cause cells to break off and form colonies distant from the original cell colony. This phenomenon may lead to the development of more specific treatments for cancerous cells.
Researchers found DNA and proteins from BK virus in prostate tissue with abnormal cell changes, a precursor stage of prostate cancer. The virus may induce uncontrolled cell growth, leading to cancer.
Researchers found that angiotensin-(1-7) significantly slows the growth of three human lung cancer cells in laboratory tests. The hormone is thought to regulate cell growth by reducing rapid proliferation and increasing cancer cell death, offering a potential new treatment approach for lung cancer.
Stanford researchers have developed a new technique to analyze cellular behavior in leukemia patients, identifying patterns that predict response to treatment. By understanding how cells respond to environmental signals, doctors can propose less common therapies and tailor treatment options to individual patients.
Researchers at the Salk Institute have discovered a critical component of the complex that enables NF-kB to trigger inflammatory responses. The study identifies ELKS protein as essential for NF-kB's function, opening new avenues for treating autoimmune diseases like lupus and arthritis.
Researchers find that combining discodermolide and paclitaxel inhibits human lung cancer cell growth by 41 percent, while alone the drugs exert only 9.6% or 16% growth inhibition. The combination also induces programmed cell death in cancer cells, suggesting a potential therapeutic approach for reducing undesirable side effects.
Researchers at UT Southwestern Medical Center discovered a protein called NHE1 that regulates cell acidity by directly detecting volume changes. This control is crucial for cell growth and proliferation. The study found specific differences in how NHE1 responds to changes in cell volume compared to another similar transporter, NHE3.
A Clemson bioengineer has created a method using laser beams to align cells in a pattern, simulating tissue environments on a small scale. This technology could lead to early detection of cancer, saving lives, by detecting cellular responses to light.
Researchers used mouse models to study how Rituximab removes human B cells, revealing that antibodies allow recognition by macrophages, which carry antibody receptors. This discovery may lead to the development of better therapies for lymphoma and autoimmune diseases like rheumatoid arthritis.
Researchers developed a new cancer treatment combining radioimmunotherapy with conventional chemotherapy, achieving complete remission in 72% of patients with follicular non-Hodgkin's lymphoma. The approach may improve treatment outcomes by targeting remaining cancer cells after chemotherapy.
Researchers discovered that stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. This finding suggests a new approach for treating cancer by targeting specific genes.
A new treatment approach has been developed to prevent autoimmune diabetes in mice by blocking the interaction between NKG2D on T cells and proteins found on abnormal cells. This breakthrough finding suggests a potential therapeutic strategy for preventing or controlling type 1 diabetes.
A study published in Journal of the National Cancer Institute found that blocking hypoxia-inducible factor 1 (HIF-1) significantly impairs tumor growth by damaging the vascular microenvironment. The tumors were smaller and had thin-walled, lumenless blood vessels compared to control mice.
A Phase III clinical trial of Tarceva and chemotherapy showed no overall benefit in survival or response, but a subgroup analysis found young non-smokers treated with Tarceva survived longer than those using chemotherapy. The study suggests that this class of drug may not function well when combined with chemotherapy.
A novel therapeutic bortezomib combination will be tested in a phase II trial for advanced non-small cell lung cancer. The regimen, combining bortezomib with gemcitabine and carboplatin, shows promise in preclinical research, where giving bortezomib last may enhance its effectiveness.
Researchers at UC Davis Cancer Center discovered that sequential administration of erlotinib and docetaxel enhances effectiveness in treating non-small cell lung cancer. The study showed that giving docetaxel first, then erlotinib, was more effective than simultaneous or alternative administration.
Researchers have found a novel agent, SU11248, to be highly effective in treating advanced renal cell carcinoma. The treatment has shown significant activity in patients whose cancer had failed to respond to standard therapy.
A study by Rockefeller University researchers reveals that a single molecular pathway controls both cell growth and death in a type of lymphoma cancer. The NF-kappa B signaling pathway, responsible for promoting cell growth, also regulates the p53 tumor suppressor protein's function, which normally destroys harmful cells.
Researchers identified more than 500 proteins contained in the midbody structure necessary for normal cell division. Inactivating these proteins led to cytokinesis defects, causing abnormal cell division, which can lead to diseases such as cancer, birth defects, and neurological disorders.
A study published in EMBO Journal found that resveratrol, a compound in grape skins, can starve cancer cells by inhibiting the action of NF-kB. This inhibition leads to apoptosis, or cell death, in cancer cells. Resveratrol's effectiveness against cancer is linked to its ability to block NF-kB's inflammatory response.
Scientists at Brown University have identified two molecular mechanisms that trigger senescence in aging cells. The discovery of p16, a protein that operates independently from telomeres, provides new insights into the regulation of cell division and holds promise for the development of therapeutics to manipulate these targets.
Researchers at Duke University Medical Center have identified a protein called Hypoxia Inducible Factor (HIF-1) as the master switch that enables blood vessels to survive and nourish remaining cancer cells after radiation therapy. By suppressing HIF-1 with experimental drugs, they successfully inhibited tumor growth in animals.
Researchers at SLU have developed oncolytic adenoviruses that target specific types of cancer cells, such as colon and lung cancer. These engineered viruses attack and destroy cancerous cells through a mechanism different from chemotherapy or radiation.
Researchers find that alkylating agents can induce necrotic cell death in cancer cells by damaging DNA and activating the PARP protein. This process is specific to proliferating cancer cells and does not affect healthy cells, offering a potential new approach to treating cancer.
Vanderbilt University Medical Center students James Peacock and Olga Weinberg have been awarded HHMI fellowships to pursue research in immunology and estrogen receptors. The fellowships will enable them to conduct academic-year-long research projects culminating in the Meeting of Medical Student Fellows.
Researchers at Ohio State University have made a breakthrough in understanding how cells package DNA, with implications for cancer research and new therapies. A newly discovered protein, Hif1p, works with an enzyme complex to add histone proteins to DNA, forming chromatin.
A study by Johns Hopkins Medicine found that a gene defect, PASG, is linked to premature aging in mice. The researchers discovered that the mutated gene causes cells to age and die prematurely, leading to growth problems and early death.
Dr. Xiaodong Wang, a professor of biochemistry at UT Southwestern Medical Center, has been elected to the National Academy of Sciences for his groundbreaking research on cell death and apoptosis. His discoveries could lead to treatments for cancer and neurological diseases.
Researchers found that administering opioid growth factor (OGF) to patients with advanced pancreatic cancer improved their quality of life and survival rates. OGF was shown to be non-toxic and did not cause common side effects associated with chemotherapy, such as hair loss or nausea.
Prostate cancer cell lines exhibit high levels of free radical damage and defective repair mechanisms, leading to a cascade of events culminating in further DNA damage and cellular dysfunction. The new research provides solid evidence for the critical role of free radicals and repair in prostate cancer development.
Researchers at UIC discovered a gene, Foxm1b, essential for the multiplication of cancer cells. A potential drug was created to block Foxm1b activity, starving tumor cells and preventing their growth.
Researchers analyzed E. coli's chemotaxis system to understand signal transduction networks, a universal design principle in nature. They found that individual variability can be regulated and carried important information about molecular mechanisms.
The U-M group uses lab-made dendrimers as the backbone of their delivery system, which can attach targeting agents to recognize cancer cells and deliver lethal doses while leaving normal cells unharmed. Early results show that nanoparticle drugs effectively treat cancer with fewer side effects than conventional chemotherapy.
Researchers at USC's Viterbi School have developed a new electric pulse technology called electroperturbation, which exposes cells to brief and intense electric pulses that can trigger cell death. The technique has advantages over conventional treatments, being non-invasive and able to deliver treatment remotely.
USC researchers have discovered a unique DNA structure linked to follicular lymphoma, the second-most common form of non-Hodgkin's lymphoma. The fragile site on chromosome 18 is responsible for 4% of all cancers and leads to the translocation 14;18, making cancer cells invincible.
SLC5A8 transporter enables the colon to absorb short-chain fatty acids, produced by bacteria fermenting plant cell walls, for energy. This finding supports eating vegetables to limit antibiotic use and promotes a healthy gut microbiome.
Researchers have discovered that low-dose HDAC inhibitors can prevent the production of inflammatory cytokines, reducing cell damage and improving survival rates in mice with GVHD. The study suggests that these drugs may be used to reduce the risk of death, hospitalization, and serious side effects associated with bone marrow transplants.
A new study by St. Jude/Mayo Clinic researchers found a direct link between the CBP gene and lymphoma development in mice, with the loss of CBP promoting T-cell lymphoma and cooperating with reduced p27Kip1 protein levels. The study suggests that CBP plays a role in cancer development despite normal p53 activity.
The Mayo Clinic's new biofusion technology targets cancer tumor cells by exploiting the natural tendency of fused cells to kill each other. This approach also promotes immune responses and repairs damaged tissues, offering a promising platform for anticancer treatment and vaccine delivery.
Researchers discovered a specialized DNA polymerase that can rescue stalled replication processes when encountering foreign material, even if it contains damage. This shows the remarkable ability of cells to reproduce and cope with genetic errors.
The study found that vinculin changes its shape in response to protein binding, enabling it to regulate cell movement and adhesion. This versatile protein plays a critical role in both healthy development and disease progression, including cancer cell spread.
Scientists have developed a method that uses allicin, found in garlic, to selectively kill cancer cells in mice. The method involves injecting an antibody and enzyme combination that targets specific receptors on cancer cells, triggering the production of lethal allicin molecules that destroy tumors while leaving healthy cells intact.
Researchers found that cancer cells release signals to nearby blood vessels to stimulate new vessel growth, while blood vessels release signals to sustain migrating cancer cells. This two-way dialogue allows cancer cells to survive and grow before new blood vessels form.
H. Steven Wiley and colleagues use systems biology to analyze the EGFR receptor network, revealing surprising complexities. They predict that lower-affinity ligands can bind longer, allowing for more effective cancer treatments.
Researchers have discovered that Heat shock protein (Hsp) 70.1 and 70.3 can be used to increase cancer cells' vulnerability to radiation treatments, offering a new treatment window for cancer patients. The proteins were found to interact with telomerase, an enzyme that helps maintain the telomeres at the ends of chromosomes.
Researchers at the University of Illinois at Urbana-Champaign have identified anastellin, a natural agent derived from the cell adhesion protein fibronectin. Anastellin stabilizes the extracellular matrix, restricting the motion of cancer cells and creating strong 'jail bars' to prevent metastasis.
A new compound has been found to selectively kill cancerous cells while leaving healthy white blood cells intact. The compound, called 13-D, induces apoptosis in cancer cells by activating caspase-3 and causing cell shrinkage, a desirable outcome as it reduces the risk of side effects.
The discovery of protein EB1 at the tip of Chlamydomonas flagella sheds new light on intraflagellar transport (IFT) and its regulation. IFT is crucial for flagellar growth and maintenance, and EB1 may play a key role in controlling the molecular transport system responsible for IFT.
Recent research suggests that at least eight central 'clock' genes coordinate cell proliferation and apoptosis in circadian time. Studies have shown that tumor growth is organized within a daily cycle, with tumors growing twice as fast during the active phase. This discovery may lead to new therapeutic targets for cancer treatment.
Researchers will discuss novel targets for controlling cancer growth, such as the circadian rhythm of cells and VEGF, a key player in tumor angiogenesis. The conference also aims to improve radiotherapy effectiveness for head and neck cancers by tailoring therapy to individual tumors.
Researchers at DMS have found that removing RIP140 allows retinoids to effectively differentiate cancer cells, slowing tumor growth and increasing the efficacy of cancer treatment. This breakthrough sheds light on the potential benefits of retinoid-based therapies for various types of cancer.
Researchers are studying the effects of low doses of radiation on zebrafish embryos to understand DNA damage and repair mechanisms. The study aims to determine the threshold for damage and whether certain genes and proteins can prevent or repair damage, with potential implications for human health.